title: Effects of medetomidine-midazolam-fentanyl IV bolus injections and its reversal by specific antagonists on cardiovascular function in rabbits.
abstract: The objective of this study was to investigate the short-term cardiovascular effects of intravenous (IV) medetomidine-midazolam-fentanyl (MMF) injections in the rabbit using vascular ultrasonography and echocardiography.Anesthesia with MMF was induced intramuscularly (IM) in 8 female New Zealand White rabbits before 3 defined bolus injections of MMF were given IV. Before and for 10 min after each MMF injection the following vascular variables [at the left common carotid artery (ACC) after the first injection and at the abdominal aorta (AA) after the second injection]: vessel diameter (D), peak systolic, minimum diastolic, end-diastolic and average blood flow velocities (psBFV, mdBFV, edBFV, Vave), average volumetric flow (VFave), resistance index (RI) and pulsatility index (PI) and other clinical variables: mean arterial pressure (MAP), heart rate (HR), peripheral arterial oxygen saturation and end-tidal CO₂ were recorded. Echocardiography was used after the third injection to investigate changes in cardiac parameters. Additionally, hemodynamic effects were observed at the ACC after complete subcutaneous antagonism of anesthesia by atipamezole-flumazenil-naloxone (AFN) until recovery of the animals.Medetomidine-midazolam-fentanyl IV caused a significant decrease of blood flow velocity in both investigated vessels which was associated with a significant decrease of HR and cardiac performance indicated by the decrease of FS and average volumetric blood flow. Mean arterial pressure significantly increased after each MMF injection; whereas, it significantly decreased after AFN injection. Therefore, MMF and AFN should be carefully used in rabbits and may not be suitable in patients with ventricular dysfunction.
authors.affiliation: Centre of Preclinical Research, Klinikum rechts der Isar, Technical University of Munich, Germany. Christine.Baumgartner@lrz.tu-muenchen.de
authors.forename: Christine
authors.initials: C
authors.lastname: Baumgartner
authors.forename: Melanie
authors.initials: M
authors.lastname: Bollerhey
authors.forename: Johanna
authors.initials: J
authors.lastname: Ebner
authors.forename: Tibor
authors.initials: T
authors.lastname: Schuster
authors.forename: Julia
authors.initials: J
authors.lastname: Henke
authors.forename: Wolf
authors.initials: W
authors.lastname: Erhardt
mesh_terms: D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D000818:Animals; D001012:Aorta, Abdominal / Q000000981:diagnostic imaging / Q000502:physiology; D001783:Blood Flow Velocity / Q000502:physiology / Q000662:veterinary; D001794:Blood Pressure / Q000502:physiology; D002319:Cardiovascular System / Q000000981:diagnostic imaging / Q000187:drug effects*; D017536:Carotid Artery, Common / Q000000981:diagnostic imaging / Q000502:physiology; D004452:Echocardiography / Q000662:veterinary; D005260:Female; D005283:Fentanyl / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006339:Heart Rate / Q000502:physiology; D016014:Linear Models; D020926:Medetomidine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008874:Midazolam / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011817:Rabbits / Q000502:physiology*
chemical_list: D018686:Anesthetics, Intravenous; D020926:Medetomidine; D008874:Midazolam; D005283:Fentanyl